Recombinant Human Follicle-Stimulating Hormone (rHFSH) Engineering Service

Recombinant Human Follicle-Stimulating Hormone (rHFSH) is a critical glycoprotein hormone used in assisted reproductive technologies (ART) for infertility treatment. Production is challenging: it is a heterodimeric glycoprotein requiring complex processing in mammalian cells. It often suffers from low expression level in CHO cells due to poor gene integration and inefficient expression machinery. Crucially, it exhibits strong glycosylation heterogeneity , where variations in the N-glycan structures (especially sialylation) directly affect its in vivo half-life and biological potency. Achieving high, consistent quality is paramount for clinical efficacy.

CD Biosynsis offers a synthetic biology service focused on engineering CHO cells for high-yield, high-quality rHFSH production. Our core strategy involves gene amplification modification of CHO cells , leveraging systems like DHFR or GS selection to dramatically increase the copy number of the FSH alpha and beta subunit genes, thereby boosting expression titers. This is coupled with the engineering of glycosyltransferase pathways. We introduce or overexpress specific human glycosyltransferases (e.g., alpha(2,6)-Sialyltransferase) and knock out unwanted host glycosylation enzymes, precisely tailoring the N-glycan profile to achieve high sialylation and the specific structure required for optimal biological activity and serum half-life. This integrated approach aims to deliver a high-yield, structurally homogeneous, and clinically superior rHFSH product.

Pain Points

Producing high-quality rHFSH in CHO cells faces these critical limitations:

• Low Expression Level: Stable integration of the FSH genes into the CHO genome often results in low copy numbers and poor transcriptional efficiency , severely limiting the final product titer.
• Strong Glycosylation Heterogeneity: FSH is heavily glycosylated. Batch-to-batch and clone-to-clone variability in sialylation, branching, and antennae structure results in inconsistent biological activity and unpredictable in vivo performance.
• Subunit Assembly Efficiency: FSH requires the correct assembly of two different subunits (alpha and beta). Inefficient or incorrect assembly leads to the accumulation of inactive free subunits , reducing yield.
• Serum Half-Life: The degree of sialylation (especially alpha(2,3) and alpha(2,6) linkages) is the primary determinant of FSH half-life in vivo . Host systems often produce sub-optimal sialylation.

A high-value solution must simultaneously boost overall expression and precisely control the final glycosylation profile.

Solutions

CD Biosynsis utilizes advanced cell line and glyco-engineering to optimize rHFSH production in CHO cells:

Gene Amplification Modification of CHO Cells

           

We employ DHFR/MTX or GS/MSX systems to select for clones with high-level gene integration and amplification, significantly boosting the FSH expression level.

Engineering of Glycosyltransferase

We overexpress key human glycosylation enzymes (e.g., alpha(2,6)-Sialyltransferase) and knock out CHO-specific enzymes (e.g., CMP-Neu5 Ac hydroxylase) to ensure human-like and optimal sialylation.

Subunit Co-expression and Assembly Optimization

We utilize bicistronic or dual-plasmid expression vectors with balanced promoter strength to ensure stoichiometric expression of alpha and beta subunits, maximizing active heterodimer formation.

Bioreactor Process Optimization

We optimize feeding strategies and culture conditions (e.g., temperature, pH) to maximize cell-specific productivity and favorably shift the glycosylation profile toward highly sialylated forms.

This systematic approach is focused on overcoming the dual challenges of low productivity and high quality requirements for complex glycoprotein pharmaceuticals.

Advantages

Our rHFSH engineering service is dedicated to pursuing the following production goals:

Dramatically Increased Titer

Gene amplification strategies lead to CHO cell lines with high-level, stable FSH expression , reducing production costs.

Optimized Serum Half-Life

Glycoengineering ensures a high degree of sialylation (especially the alpha(2,3) linkage) , maximizing the in vivo efficacy of the drug.

Reduced Glycosylation Heterogeneity

Precise transferase control results in a more structurally homogeneous product , ensuring consistent batch-to-batch quality and activity.

Enhanced Bioactivity

Optimized N-glycans are known to increase the receptor binding affinity and overall biological potency of FSH.

Regulatory Compliance

Engineered CHO cell lines avoid non-human epitopes like Neu5 Gc that can raise regulatory concerns.

We provide a specialized cell line engineering platform aimed at maximizing the quality and cost-effectiveness of clinical-grade rHFSH biomanufacturing.

Process

Our rHFSH cell line engineering service follows a rigorous, multi-stage research workflow:

• Vector Design and Co-integration: Design expression vectors ensuring balanced alpha and beta subunit expression alongside the DHFR or GS selection marker.
• Gene Amplification and Cell Cloning: Apply gradually increasing concentrations of selection agent (MTX or MSX) to select for highly amplified, high-producing clones .
• Glycosylation Pathway Modification: Utilize CRISPR technology to knock out unwanted host glycosyltransferases and stably introduce target human enzymes (e.g., alpha(2,3) and alpha(2,6)-Sialyltransferase).
• Clonal Stability and Quality Assessment: Evaluate the final clones for genetic stability, expression titer , and conduct detailed analysis of the N-glycan profile (e.g., by CE or HPLC).
• Bioactivity Assay: Confirm the final product’s activity using established in vitro functional assays (e.g., cAMP stimulation assay) to ensure clinical relevance.
• Result Report Output: Compile a detailed Experimental Report including cell line documentation, FSH titer, and quantitative glycan analysis , supporting IND submission.

Technical communication is maintained throughout the process, focusing on timely feedback regarding titer, quality, and homogeneity.

Explore the potential for a high-quality, cost-effective rHFSH supply. CD Biosynsis provides customized cell line solutions:

• Detailed Titer and Glycan Profile Analysis Report , demonstrating the degree of expression enhancement and glycosylation control achieved.
• Consultation on scale-up and cGMP compliance for the engineered CHO cell line.
• Experimental reports include complete raw data on volumetric productivity (mg/L/day) and glycan structural distribution , essential for regulatory approval.